0300 ket No: AHP 98126 P2

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Ozenberger, et al.

Serial No.O\PE

09/852,100 May 9, 2001 Group Art No.:

TBD

Filed:

Examiner:

TBD

For:

Beta-Amyloid Peptide-Binding Proteins and Polynucleotides Encoding

Confirmation

the Same TBD

Customer Number:

25291

Commissioner for Patents

Box DD

Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

1. **Preliminary Statements**

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL564797277US addressed to the Commissioner for Patents, Box DD, Washington, DC 20231.

Docket No: AHP 98126 P2 Patent

2.		fication of Time of Filing	
		nformation Disclosure Statement	
	a.	is filed within three months of the filing date of the application.	
	b.	is filed before the mailing date of a first Office Action on the merits.	
	c.	is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.	
	d.	is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes certification under 37 CFR 1.97(a) or the fee set forth in 37 CFR 1.17(a)	a
	e.	certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p). is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).	
3.		Certification under 37 CFR 1.97(e) The undersigned attorney certifies	
	a.	that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filin of the statement, or	ıg
	b.	that no item of information contained in the Information Disclosure Statemer was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.	ion
	c.	The undersigned attorney certifies that each item of information contained it the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirt (30) days prior to the filing of the statement.	ıs
		Newly Cited Information A legible copy of the patents, publications or other information cited on the attachform PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.	ed
	\boxtimes	Previously Cited Information	
		No copy of the patents, publications or other information cited on the attached for	m
		PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35	
		USC 120. Prior application is Serial Number 09/774,936, filed on January 31, 2001 of Bradle A. Ozenberger, Jonathan A. Bard, Eileen M. Kajkowski, Jack S. Jacobsen, Stepher G. Walker, Heidi Sofia, & David Howland for Beta-Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same.	

Decket No: AHP 98126 P2
Patent

	Concise Explanation
	Documents cited above which are not in the English Language
a.	have been explained in the specification.
b.	have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.
Form	PTO-1449 is enclosed in duplicate.
	Fees
	Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00
Meth	od of Payment of Fees:
	ge Deposit Account No. 01-1425 in the amount of \$0.00
A du	plicate of this statement is enclosed.
Instru	actions as to Overpayment/Underpayment:
Credi	t any overpayment and charge any underpayment to Deposit Account No. 01-1425.
	\mathcal{M}
	The

See Attached Certificate

Gavin T. Bogle

American Home Products Corporation Patent Law Department Five Giralda Farms Madison, NJ 07940-0874 Tel. No. (617) 665-8079

r		
LIST OF PATENT AND PUBLICATION FOR APPLIC INFORMATION DISCLOSUR STATEMENT (USE SEVERAL SHEETSOF)		Application No.: 09/852,100
()111	Applicant(s): B.A. Ozenberger et	et al.
PET	Filing Date: May 9, 2001	Group Art Unit:
81	RADEM US PATENT DOCUMENTS	

Examiner Initial		Doc. No.	Date	Name	Class	Sub-Class	Filing Date
	AA			17. 17.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Doc. No.	Date	Country	Class	Sub-Class	Transla Yes	ation No
	AL	WO 96/25435	22 Aug 96	PCT				
	AM	WO 88/03951	2 Jun 88	PCT		:		Ì
	AN	WO 96/13513	9 May 96	PCT				
	AO	WO 98/46636	22 Oct 98	PCT		-		
	AP	WO 99/46289	16 Sep 99	PCT				
	AQ	WO 99/24836	20 May 99	PCT				
	AL2	WO 00/22125	20 Apr 00	PCT			<u> </u>	

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

1.	AR	J. Biol. Chem., "Modulation of GDP Release from Transducin by the Conserved Glu ¹³⁴ Arg ¹³⁵ Sequence in Rhodopsin", S. Acharya et al., <u>271</u> , No. 41, (Oct. 1996) pp. 25406-411;
2.	AS	J. Mol. Biol., "Basic Local Alignment Search Tool", S.F. Altschul et al., (1990) <u>215,</u> pp. 403-410;
3.	AT	Lett. Nature, "Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor", F. Revah et al., <u>353</u> , (Oct. 1991), pp. 846- ;

PTO 1449.doc Sheet 1 of 5

		OTHER DOCUMENTS Procedure author, title, date, pertinent pages, etc.)
4.	AU	Nature, "RAGE and myloid-β-peptite neurotoxicity in Alzheimer's disease", Shi Du Yan et al., 382, (Aug. 1996) pp. 685-691;
		JUL 1 9 2001
5.	AV	Nature, "Scavenger repetor-mediates adhesion of microglia to β-amyloid fibrils", J. El Khoury et al., 382 (Aug. 1996), pp. 716-719;
6.	AW	Nature, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease", <u>349</u> (Feb. 1991), pp. 704-706;
7.	AX	Nature Genetics, "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene", L. Hendriks et al., 1 (June 1992), pp. 218-221.
8.	AY	Neurobiology of Aging, "A novel species-specific RNA related to alternatively spliced amyloid precursor protein mRNAs", J.S. Jacobsen et al., <u>12</u> , (1991) pp. 575-583.
9.	47	L Biol Character and Alabaira de Proposition de Pro
9.	AZ	J. Biol. Chem., "The release of Alzheimer's disease β amyloid peptide is reduced by phorbol treatment", J.S. Jacobsen et al., <u>269</u> , No. 11 (March 1994), pp. 8376-8382.
10.	AR2	Mal Call Biol "Effects of symposium of mammalian Co. and hybrid mammalian uses Co. materia and hybrid
10.	Anz	Mol. Cell. Biol., "Effects of expression of mammalian $G\alpha$ and hybrid mammalian yeast $G\alpha$ proteins on the yeast pheromone response signal transduction pathway", Yoon-Se Kang et al., <u>10</u> , No. 6 (June 1990), pp. 2582-2590.
11.	AS2	Nat. Genetics, "The Alzheimer's Aβ peptide induces neurodegeneration nd apoptotic cell death in transgenic mice", 9, (Jan. 1995), pp.21-30.
	 	inice , <u>s</u> , (Jan. 1993), pp.21-30.
12.	AT2	A. Neuropathol., "Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ", H. Lassman et al., 89 (Springer-Vertaag 1995), pp. 35-41.
13.	AU2	Science, "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type", 243, (June 1990), pp. 1124-1126.
14.	AV2	Proc. Natl. Acad. Sci., "Apoptosis is induced by β-amyloid in cultured central nervous system neurons", D.T. Loo et al., <u>90</u> , (Sept. 1993), pp. 7951-7955.
15.	AW2	Proc. Natl. Acad. Sci., "Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide", J.E. Maggio et al., 89 (June 1992), pp. 5462-5466.
16.	AX2	Nat. Genetics, "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid", M. Mullan et al., 1 (Aug. 1992), pp. 345-347.

PTO 1449.doc

OTHER DOCUMENTS (Including author, Met, page, pertinent	pages, etc.)
---	--------------

		OTHER DOCUMENTS (Including author Ale, pages, etc.)
17.	AY2	Sci., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease", J. Murrell et al., 254 (Oct. 1991), pp. 97-99.
18.	AZ2	Lett. Nat., "Alzheimer amyloid protein precurs of completes with brain GTP-binding protein G _o ", I. Nishimoto et al., <u>362</u> (March 1993), pp. 75-79.
19.	AR3	Nature Medicine, "Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease", D. Scheuner et al., 2 No. 8 (Aug. 1996), pp. 864-70.
		· ·
20.	AS3	Science, "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", D.J. Selkoe, <u>275</u> (Jan. 1997), pp. 630-31.
21.	AT3	J. Neurosci., "Voltage-gated K ⁺ channel β subunits: Expression and distribution of Kvβ1 and Kvβ2 in adult rat brain", K.J. Rhodes et al., <u>16</u> (Aug. 1996), pp. 4846-60.
22.	AU3	Mol. Endo., "Functional interaction of ligands and receptors of the hematopoietic superfamily in yeast", B.A. Ozenberger et al., <u>9</u> No. 10 (1995), pp. 1321-29.
23.	AV3	Exp. Neurology, "Evidence of apoptotic cell death in Alzheimer's disease", G. Smale et al., <u>133</u> (1995), pp. 225-30.
24.	AW3	Sci., "Amyloid β protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus", (Jan. 1987), pp. 880-84.
25.	АХЗ	Proc. Natl. Acad. Sci., "Detection of conserved segments in proteins: Iterative scanning of sequence databases with alignment blocks",R.L. Tatusov et al., <u>91</u> (Dec. 1994), pp. 12091-95.
26.	AY3	Cell, "The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases", J. Wade Harper et al., <u>75</u> (Nov. 1993), pp. 805-16.
27.	AZ3	Elsevier Sci., "Ultrastructural analysis of β-amyloid-induced apoptosis in cultured hippocampal neurons", J.A. Watt et al., <u>661</u> (1994), pp. 147-156.
28.	AR4	Sci., "G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP", T. Yamatsuji et al., <u>272</u> (May 1996), pp. 1349-52.
29.	AS4	Nature, "An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease", Shi Du Yan et al., <u>389</u> (Oct. 1997), pp. 689-

PTO 1449.doc

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

		OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)
30.	AT4	Science, Lewin, <u>237</u> (1987), p. 1570.
		JU 4 5 50
31.	AU4	Biotech Adv., Gellissen et al., <u>10</u> (1992), pp. 179-189
		A PADEMARK OFFICE
32.	AV4	Nature, Adams et al., <u>377</u> (1995), pp. 3-174.
33.	AW4	Genbank Accession Number AA306979, Adams et al., 1995.
34.	AX4	Glossary of Genetics and Cytogenetics, Rieger et al., 1976, pp. 17-18.
35.	AY4	Journal of Cell Biology, Burgess et al., <u>111</u> (1990), pp. 2129-2138.
36.	AZ4	Molecular and Cellular Biology, Lazar et al., <u>8(3)</u> (March 1988), pp. 1247-1252.
37.	AR5	"Peptide Hormones," Rudinger, University Park Press, June 1976, pp. 1-7.
38.	AS5	"Molecular Cloning," Sambrook et al., Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp. 17.1-17.44.
39.	AT5	DATABASE EMBL - EMEST7 'Online! Entry/Acc.no. Al143226, 29 September 1998 (1998-09-29) Strausberg, R., "qb76e01.x1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:1706040 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA sequence." XP002135394
40.	AU5	DATABASE EMBL - EMEST1 'Online! Entry/Acc.no. AA628537, 28 October 1997 (1997-10-28) Hillier, L., et al., "af27h04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032919 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN;." XP002135395
41.	AV5	DATABASE EMBL - EMEST3 'Online! Entry/Acc.no. AA772225, 31 January 31, 1998 (1998-01-31) Strausberg, R., et al., "ai41c01.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone 1359552 3' similar to WP:C02F5.3 CE00039 GTP-BINDING PROTEIN; mRNA" XP002135396
42.	AW5	Proc. Nat'l. Acad. Sci. USA, "Expression, stability, and membrane integration of truncation mutants of bovine rhodopsin," Heymann, J.A.W., et al., <u>94</u> (1997), pp. 4966-4971.

PTO 1449.doc Sheet 4 of 5

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.) FASEB Journal, "A novel family of apoptosis modulators contain a G protein coupling motif," AX5 43. Kajkowski, E., et al., 13 (1999), pp. A1434-Abstr. 589. DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES 10 May 1996 XP002081589 44. AY5 HINXTON, GB, AC=W29859. Soares mouse p3NMF 19.5 Mus muscelles DNA clone 348008 5'. similar to GTP-BINDING PROTEIN. 45. AZ5 The Journal of Biological Chemistry, "Arrest of beta-amyloid fibril formation by a peptapeptide ligand," Tjernberg, L.O., et al., 271 (1996), pp. 8545-8548. DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 22 July 1998, XP002081601 AR6 46 HINXTON, GB, AC=Al057115. Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone, similar to GTP-binding protein. Spans from nt 3260632; Spans from aa residues 1-101. Exami **Date Considered:** ner: *Examiner: Initial if reference considered, whether or not citation is in conformance with MPRP 609; Draw line through citation if not inconformance and not considered. Include coy of this form with next communication to applicant.